CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine

Qiu,Zheng; Xing,Lijun; Zhang,Xueqing; Qiang,Xu; Xu,Yifeng; Zhang,Mei; Zhou,Zhengpin; Zhang,Juan; Zhang,Fang; Wang,Min

doi:10.3892/or.2017.5633

CpG oligodeoxynucleotides augment antitumor efficacy of folate receptor α based DNA vaccine

Authors:
- Zheng Qiu
- Lijun Xing
- Xueqing Zhang
- Xu Qiang
- Yifeng Xu
- Mei Zhang
- Zhengpin Zhou
- Juan Zhang
- Fang Zhang
- Min Wang
View Affiliations

Affiliations: School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China
Published online on: May 8, 2017 https://doi.org/10.3892/or.2017.5633
Pages: 3441-3448

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Folate receptor α (FRα) is overexpressed in a variety of solid tumors and has become an attractive target antigen for immunotherapy purposes. A DNA vaccine was generated by ligation of FRα cDNA into the eukaryotic vector pcDNA3.1. Expression of FRα was confirmed in transiently transfected B16 cells. B16 cell lines that stably express FRα were set up by G418 selection. A total of 100 µg purified plasmid DNA alone or in combination with CpG oligodeoxynucleotides (CpG ODN) was injected intramuscularly in C57BL/6 mice four times at one week intervals. ELISA analysis confirmed that high titers of antibodies against FRα existed in the sera of the experimental animals. Specific cytotoxic T lymphocyte activity against FRα-expressing B16 cells was found and FRα specific lymphocyte proliferation was detected. Coinjection of CpG ODN increased both humoral and cellular immune responses. In the protective model, in which C57BL/6 mice were immunized with the FRα DNA vaccine four weeks before tumor cell inoculation, the growth of tumor was significantly inhibited, and the presence of CpG ODN further increased the inhibitory effect. FRα DNA vaccine alone did not show a significant inhibitory effect in the therapeutic model, in which the DNA vaccine was immediately injected after tumor inoculation. However, FRα DNA vaccine plus CpG ODN showed a significant inhibitory effect in tumor growth. Survival curves for both animal experiments confirmed that mice immunized with pcDNA3.1/FRα plus CpG ODN had a significantly prolonged survival period than that of the pcDNA3.1 control group, the CpG ODN group or the pcDNA3.1/FRα group. The above showed that human FRα based DNA vaccination with CpG ODN as an adjuvant was effective in growth inhibition of a FRα expressing tumor in mice and deserves further evaluation as a possible immunotherapy.

View Figures

View References

1	Delany I, Rappuoli R and De Gregorio E: Vaccines for the 21st century. EMBO Mol Med. 6:708–720. 2014.PubMed/NCBI
2	Vanneman M and Dranoff G: Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 12:237–251. 2012. View Article : Google Scholar : PubMed/NCBI
3	Houghton AN: Cancer antigens: Immune recognition of self and altered self. J Exp Med. 180:1–4. 1994. View Article : Google Scholar : PubMed/NCBI
4	Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A and Felgner PL: Direct gene transfer into mouse muscle in vivo. Science. 247:1465–1468. 1990. View Article : Google Scholar : PubMed/NCBI
5	Fioretti D, Iurescia S, Fazio VM and Rinaldi M: DNA vaccines: Developing new strategies against cancer. J Biomed Biotechnol. 2010:1743782010. View Article : Google Scholar : PubMed/NCBI
6	Li L, Saade F and Petrovsky N: The future of human DNA vaccines. J Biotechnol. 162:171–182. 2012. View Article : Google Scholar : PubMed/NCBI
7	Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 5:190–198. 2004. View Article : Google Scholar : PubMed/NCBI
8	Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 5:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
9	Klinman DM, Currie D, Lee G, Grippe V and Merkel T: Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect. 9:1478–1483. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ohno S, Okuyama R, Aruga A, Sugiyama H and Yamamoto M: Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 32:2263–2269. 2012.PubMed/NCBI
11	Mutwiri GK, Nichani AK, Babiuk S and Babiuk LA: Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 97:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
12	Vollmer J and Krieg AM: Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 61:195–204. 2009. View Article : Google Scholar : PubMed/NCBI
13	Halperin SA, van Nest G, Smith B, Abtahi S, Whiley H and Eiden JJ: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine. 21:2461–2467. 2003. View Article : Google Scholar : PubMed/NCBI
14	Elnakat H and Ratnam M: Role of folate receptor genes in reproduction and related cancers. Front Biosci. 11:506–519. 2006. View Article : Google Scholar : PubMed/NCBI
15	Parker N, Turk MJ, Westrick E, Lewis JD, Low PS and Leamon CP: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 338:284–293. 2005. View Article : Google Scholar : PubMed/NCBI
16	Basal E, Eghbali-Fatourechi GZ, Kalli KR, Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS and Knutson KL: Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One. 4:e62922009. View Article : Google Scholar : PubMed/NCBI
17	Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL and Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 108:619–626. 2008. View Article : Google Scholar : PubMed/NCBI
18	Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M and Boiocchi M: Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 74:193–198. 1997. View Article : Google Scholar : PubMed/NCBI
19	Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, O'Shannessy DJ, Somers EB and Vergote I: Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol. 130:192–199. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, et al: Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun. 7:6–13. 2007.PubMed/NCBI
21	Armstrong DK, White AJ, Weil SC, Phillips M and Coleman RL: Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 129:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
22	Walters CL, Arend RC, Armstrong DK, Naumann RW and Alvarez RD: Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer. Gynecol Oncol. 131:493–498. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chu RS, Targoni OS, Krieg AM, Lehmann PV and Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 186:1623–1631. 1997. View Article : Google Scholar : PubMed/NCBI
24	Hailemichael Y and Overwijk WW: Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int J Biochem Cell Biol. 53:46–50. 2014. View Article : Google Scholar : PubMed/NCBI
25	Lindblad EB: Aluminium compounds for use in vaccines. Immunol Cell Biol. 82:497–505. 2004. View Article : Google Scholar : PubMed/NCBI
26	Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM and Cameron DW: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 19:1473–1479. 2005. View Article : Google Scholar : PubMed/NCBI
27	Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, Gonzalez C, Manukian G, Wang J, Zhang Y, Chapman PB, et al: Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther. 16:2022–2029. 2008. View Article : Google Scholar : PubMed/NCBI
28	Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, et al: WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother. 59:1467–1479. 2010. View Article : Google Scholar : PubMed/NCBI
29	Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, et al: Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 26:4418–4425. 2008. View Article : Google Scholar : PubMed/NCBI
30	Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, Lopez-Brea M, Vanakesa T, Jassem J, Kalofonos H, et al: Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results. J Clin Oncol. 31:2396–2403. 2013. View Article : Google Scholar : PubMed/NCBI
31	Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, et al: Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer. 130:2607–2617. 2012. View Article : Google Scholar : PubMed/NCBI
32	Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC and Romero P: Rapid and strong human CD8⁺ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 115:739–746. 2005. View Article : Google Scholar : PubMed/NCBI
33	Neglia F, Orengo AM, Cilli M, Meazza R, Tomassetti A, Canevari S, Melani C, Colombo MP and Ferrini S: DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther. 6:349–357. 1999. View Article : Google Scholar : PubMed/NCBI